Do Not Take Auvelity and Wellbutrin Together
Auvelity already contains bupropion (the active ingredient in Wellbutrin), so taking them together would result in excessive bupropion exposure, significantly increasing the risk of seizures and other serious adverse effects. This combination is contraindicated.
Why This Combination is Dangerous
Auvelity is a fixed-dose combination product containing dextromethorphan 45 mg and bupropion 105 mg per tablet, with a maximum recommended dose of 2 tablets daily (total daily bupropion: 210 mg) 1. Adding Wellbutrin to this regimen would create a dangerous duplication of bupropion therapy.
Critical Safety Concerns
Seizure Risk: Bupropion dose-dependently lowers the seizure threshold 1. The risk increases substantially with:
- Total daily doses exceeding recommended limits
- Rapid dose escalation
- Concurrent conditions that predispose to seizures (eating disorders, alcohol/benzodiazepine withdrawal, head trauma, CNS tumors)
Taking both medications simultaneously would push bupropion levels well beyond safe therapeutic ranges, dramatically elevating seizure risk.
Other Serious Adverse Effects from Excessive Bupropion:
- Hypertension (requires blood pressure monitoring even at therapeutic doses) 2
- Neuropsychiatric effects including agitation, anxiety, insomnia
- Increased suicidal ideation risk, particularly in patients under 24 years 1
- Cardiovascular effects (though long-term cardiovascular safety data remain incomplete) 2
Understanding Auvelity's Unique Mechanism
The bupropion component in Auvelity serves a dual purpose 1:
- Antidepressant activity through norepinephrine and dopamine reuptake inhibition
- CYP2D6 inhibition that increases dextromethorphan bioavailability by 20-32 fold at steady state
This pharmacokinetic interaction is intentional and therapeutic—the bupropion dose is specifically calibrated to optimize dextromethorphan levels while maintaining antidepressant efficacy 1. Adding external bupropion disrupts this carefully balanced formulation.
Clinical Scenarios and Alternatives
Switching from Wellbutrin to Auvelity
If a patient is currently on Wellbutrin and requires Auvelity:
- Discontinue Wellbutrin completely before initiating Auvelity
- No washout period is typically required given bupropion's 15-hour half-life (though hydroxybupropion metabolites have longer half-lives of 33-44 hours) 1
- Start Auvelity at the standard dose: 1 tablet daily in the morning for 3 days, then increase to 1 tablet twice daily 1
If Depression is Inadequately Controlled on Wellbutrin Alone
Rather than adding Auvelity (which would duplicate bupropion), consider:
Augmentation strategies with non-bupropion agents:
- Aripiprazole augmentation showed higher remission rates (55.4%) compared to bupropion augmentation (34.0%) in treatment-resistant depression 3
- Switching to a different antidepressant class entirely
- Considering Auvelity as a replacement (not addition) if rapid onset is desired—clinical trials showed significant MADRS score reductions as early as week 1 4, 5
Special Populations Requiring Dose Adjustments
If switching to Auvelity, note these contraindications and adjustments 1:
Renal impairment:
- Moderate (eGFR 30-59): Reduce to 1 tablet daily maximum
- Severe (eGFR 15-29): Not recommended
Hepatic impairment:
- Severe (Child-Pugh C): Not recommended
CYP2D6 poor metabolizers: Reduce to 1 tablet daily maximum (dextromethorphan levels will be even higher)
Common Pitfalls to Avoid
Assuming "more is better": The therapeutic benefit of Auvelity comes from the synergistic dextromethorphan-bupropion combination at specific ratios, not from maximizing bupropion dose 1
Overlooking drug interactions: Both medications interact with MAOIs (14-day washout required), opioids (naltrexone component in some obesity formulations can precipitate withdrawal), and medications metabolized by CYP2D6 1
Ignoring psychiatric history: While bupropion monotherapy at 300 mg daily is FDA-approved for depression 2, the combination product was not extensively studied in patients with serious psychiatric illness or those on other antidepressants 6, 2
Missing seizure risk factors: Carefully screen for eating disorders (anorexia/bulimia), substance withdrawal states, and other conditions that lower seizure threshold before prescribing either medication 1
The bottom line: Auvelity and Wellbutrin contain the same active ingredient (bupropion) and must never be combined. Choose one or the other based on clinical indication—Auvelity if rapid antidepressant onset is desired, or Wellbutrin if standard bupropion monotherapy is appropriate.